vs
Apellis Pharmaceuticals, Inc.（APLS）与Perimeter Solutions, Inc.（PRM）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Perimeter Solutions, Inc.的1.9倍（$199.9M vs $102.8M），Apellis Pharmaceuticals, Inc.净利率更高（-29.5% vs -136.5%，领先107.0%），Perimeter Solutions, Inc.同比增速更快（19.2% vs -5.9%），Perimeter Solutions, Inc.自由现金流更多（$11.6M vs $-14.3M），过去两年Perimeter Solutions, Inc.的营收复合增速更高（31.9% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Perimeter Solutions是一家以色列云与网络安全企业，专为各类机构打造基于零信任架构的安全远程网络方案，其技术可替代VPN、防火墙等传统安全硬件设备，助力企业简化网络安全部署，提升远程访问的安全性与效率。
APLS vs PRM — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $102.8M |
| 净利润 | $-59.0M | $-140.2M |
| 毛利率 | — | 45.2% |
| 营业利润率 | -25.6% | -160.7% |
| 净利率 | -29.5% | -136.5% |
| 营收同比 | -5.9% | 19.2% |
| 净利润同比 | -62.2% | -197.3% |
| 每股收益（稀释后） | $-0.40 | $-0.89 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $102.8M | ||
| Q3 25 | $458.6M | $315.4M | ||
| Q2 25 | $178.5M | $162.6M | ||
| Q1 25 | $166.8M | $72.0M | ||
| Q4 24 | $212.5M | $86.2M | ||
| Q3 24 | $196.8M | $288.4M | ||
| Q2 24 | $199.7M | $127.3M | ||
| Q1 24 | $172.3M | $59.0M |
| Q4 25 | $-59.0M | $-140.2M | ||
| Q3 25 | $215.7M | $-90.7M | ||
| Q2 25 | $-42.2M | $-32.2M | ||
| Q1 25 | $-92.2M | $56.7M | ||
| Q4 24 | $-36.4M | $144.2M | ||
| Q3 24 | $-57.4M | $-89.2M | ||
| Q2 24 | $-37.7M | $21.6M | ||
| Q1 24 | $-66.4M | $-82.6M |
| Q4 25 | — | 45.2% | ||
| Q3 25 | — | 63.1% | ||
| Q2 25 | — | 62.4% | ||
| Q1 25 | — | 39.1% | ||
| Q4 24 | — | 48.6% | ||
| Q3 24 | — | 62.8% | ||
| Q2 24 | — | 57.6% | ||
| Q1 24 | — | 35.1% |
| Q4 25 | -25.6% | -160.7% | ||
| Q3 25 | 48.7% | -27.7% | ||
| Q2 25 | -18.6% | -16.1% | ||
| Q1 25 | -50.0% | — | ||
| Q4 24 | -12.3% | 71.1% | ||
| Q3 24 | -24.0% | -12.2% | ||
| Q2 24 | -14.7% | 35.4% | ||
| Q1 24 | -36.0% | -126.8% |
| Q4 25 | -29.5% | -136.5% | ||
| Q3 25 | 47.0% | -28.7% | ||
| Q2 25 | -23.6% | -19.8% | ||
| Q1 25 | -55.3% | 78.7% | ||
| Q4 24 | -17.1% | 167.2% | ||
| Q3 24 | -29.2% | -30.9% | ||
| Q2 24 | -18.9% | 17.0% | ||
| Q1 24 | -38.5% | -139.8% |
| Q4 25 | $-0.40 | $-0.89 | ||
| Q3 25 | $1.67 | $-0.62 | ||
| Q2 25 | $-0.33 | $-0.22 | ||
| Q1 25 | $-0.74 | $0.36 | ||
| Q4 24 | $-0.30 | $1.00 | ||
| Q3 24 | $-0.46 | $-0.61 | ||
| Q2 24 | $-0.30 | $0.14 | ||
| Q1 24 | $-0.54 | $-0.57 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $325.9M |
| 总债务越低越好 | — | $669.1M |
| 股东权益账面价值 | $370.1M | $1.1B |
| 总资产 | $1.1B | $2.7B |
| 负债/权益比越低杠杆越低 | — | 0.59× |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $325.9M | ||
| Q3 25 | $479.2M | $340.6M | ||
| Q2 25 | $370.0M | $140.7M | ||
| Q1 25 | $358.4M | $200.1M | ||
| Q4 24 | $411.3M | $198.5M | ||
| Q3 24 | $396.9M | $223.1M | ||
| Q2 24 | $360.1M | $43.2M | ||
| Q1 24 | $325.9M | $38.7M |
| Q4 25 | — | $669.1M | ||
| Q3 25 | — | $668.8M | ||
| Q2 25 | — | $668.4M | ||
| Q1 25 | — | $668.1M | ||
| Q4 24 | — | $667.8M | ||
| Q3 24 | — | $667.4M | ||
| Q2 24 | — | $667.1M | ||
| Q1 24 | $93.1M | $666.8M |
| Q4 25 | $370.1M | $1.1B | ||
| Q3 25 | $401.2M | $1.1B | ||
| Q2 25 | $156.3M | $1.2B | ||
| Q1 25 | $164.2M | $1.2B | ||
| Q4 24 | $228.5M | $1.2B | ||
| Q3 24 | $237.1M | $1.0B | ||
| Q2 24 | $264.3M | $1.1B | ||
| Q1 24 | $266.7M | $1.1B |
| Q4 25 | $1.1B | $2.7B | ||
| Q3 25 | $1.1B | $2.6B | ||
| Q2 25 | $821.4M | $2.5B | ||
| Q1 25 | $807.3M | $2.4B | ||
| Q4 24 | $885.1M | $2.4B | ||
| Q3 24 | $901.9M | $2.5B | ||
| Q2 24 | $904.5M | $2.3B | ||
| Q1 24 | $831.9M | $2.3B |
| Q4 25 | — | 0.59× | ||
| Q3 25 | — | 0.60× | ||
| Q2 25 | — | 0.57× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.58× | ||
| Q3 24 | — | 0.67× | ||
| Q2 24 | — | 0.62× | ||
| Q1 24 | 0.35× | 0.63× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $18.6M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $11.6M |
| 自由现金流率自由现金流/营收 | -7.1% | 11.3% |
| 资本支出强度资本支出/营收 | 0.1% | 6.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $208.6M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $18.6M | ||
| Q3 25 | $108.5M | $198.7M | ||
| Q2 25 | $4.4M | $-2.9M | ||
| Q1 25 | $-53.4M | $23.7M | ||
| Q4 24 | $19.4M | $-6.0M | ||
| Q3 24 | $34.1M | $183.0M | ||
| Q2 24 | $-8.3M | $8.6M | ||
| Q1 24 | $-133.0M | $2.8M |
| Q4 25 | $-14.3M | $11.6M | ||
| Q3 25 | $108.3M | $193.6M | ||
| Q2 25 | $4.4M | $-15.6M | ||
| Q1 25 | $-53.4M | $18.9M | ||
| Q4 24 | $19.3M | $-12.4M | ||
| Q3 24 | — | $179.1M | ||
| Q2 24 | $-8.4M | $5.0M | ||
| Q1 24 | $-133.3M | $1.2M |
| Q4 25 | -7.1% | 11.3% | ||
| Q3 25 | 23.6% | 61.4% | ||
| Q2 25 | 2.5% | -9.6% | ||
| Q1 25 | -32.0% | 26.3% | ||
| Q4 24 | 9.1% | -14.4% | ||
| Q3 24 | — | 62.1% | ||
| Q2 24 | -4.2% | 3.9% | ||
| Q1 24 | -77.3% | 2.1% |
| Q4 25 | 0.1% | 6.8% | ||
| Q3 25 | 0.0% | 1.6% | ||
| Q2 25 | 0.0% | 7.8% | ||
| Q1 25 | 0.0% | 6.7% | ||
| Q4 24 | 0.0% | 7.5% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | 0.0% | 2.9% | ||
| Q1 24 | 0.2% | 2.6% |
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.42× | ||
| Q4 24 | — | -0.04× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.40× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
PRM
| Products | $87.7M | 85% |
| Service And Other | $14.8M | 14% |
